Literature DB >> 20048391

Increased vascular access complications in patients with renal dysfunction undergoing percutaneous coronary procedures using arteriotomy closure devices.

Emad F Aziz1, Sandeep Pulimi, Clinton Coleman, Calatin Florita, Dan Musat, Deborah Tormey, Ashraf Fawzy, Steve Lee, Eyal Herzog, David L Coven, Jacqueline Tamis-Holland, Mun K Hong.   

Abstract

BACKGROUND: Arteriotomy closure device (ACD) use has increased following percutaneous transfemoral coronary procedures (PTCP). However, their safety in patients with chronic kidney disease (CKD) is not known. Therefore, we evaluated the complication rates of ACD among patients with CKD.
METHODS: Six-hundred ten consecutive patients who underwent PTCP and ACD were retrospectively studied. Patients were grouped according to their creatinine clearance (CrCl in ml/min/1.73 m2) calculated by the Cockcroft-Gault formula using the National Kidney Foundation classification system; Stage I (CrCl > or = 90); Stage II (60-89); Stage III (30-59); Stage IV (15-29); and Stage V (< or = 15). The primary endpoint was the combined incidence of pseudoaneurysm, retroperitoneal hematoma, femoral artery thrombosis, surgical vascular repair, and groin infection.
RESULTS: Among 610 patients 283 (46%) underwent PCI. The primary endpoint was seen in 66 (10.8%) patients. Univariate predictors of primary outcome were lower CrCl (p < 0.001), and presence of peripheral vascular disease (p = 0.03). There was an inverse relationship between CrCl and complication rate. CKD was the strongest independent multivariate predictor for the primary endpoint (OR 1.032; 95% CI 1.019-1.046; p < 0.0001), driven by higher infection (p < 0.0001), thrombosis (p = 0.003) and hematoma (p = 0.007).
CONCLUSIONS: Renal function appears to be significantly associated with vascular access-site complications. Worsening renal function is associated with higher vascular access site complications, largely driven by an increased infection rate.

Entities:  

Mesh:

Year:  2010        PMID: 20048391

Source DB:  PubMed          Journal:  J Invasive Cardiol        ISSN: 1042-3931            Impact factor:   2.022


  6 in total

Review 1.  Revascularization Strategies in Patients with Chronic Kidney Disease and Acute Coronary Syndromes.

Authors:  Evan C Klein; Ridhima Kapoor; David Lewandowski; Peter J Mason
Journal:  Curr Cardiol Rep       Date:  2019-08-30       Impact factor: 2.931

2.  Initial experience with the AXERA 2 Femoral Access System in neurovascular procedures.

Authors:  Ramesh Grandhi; Nathan T Zwagerman; Xiaoran Zhang; Stephanie H Chen; Ashutosh P Jadhav; Tudor Jovin; Brian T Jankowitz
Journal:  Interv Neuroradiol       Date:  2015-05-26       Impact factor: 1.610

3.  Incidence of delayed angiographic femoral artery complications using the EXOSEAL vascular closure device.

Authors:  Ramesh Grandhi; Xiaoran Zhang; David Panczykowski; Phillip Choi; Christopher T Hunnicutt; Ashutosh P Jadhav; Andrew F Ducruet; Tudor Jovin; Brian Jankowitz
Journal:  Interv Neuroradiol       Date:  2015-05-26       Impact factor: 1.610

4.  Feasibility and Safety of Coronary Procedures via an Arteriovenous Graft Approach in Patients on Maintenance Hemodialysis.

Authors:  Rye-Cheng Ko; Min-Tsun Liao; Lin Lin; Mu-Yang Hsieh; Pei-Shan Lin; Kuei-Chin Tsai; Chia-Lun Chao; Chih-Cheng Wu
Journal:  Acta Cardiol Sin       Date:  2015-11       Impact factor: 2.672

5.  Transradial access for renal artery intervention.

Authors:  Zoltán Ruzsa; Károly Tóth; Zoltán Jambrik; Nándor Kovács; Sándor Nardai; Balázs Nemes; Kálmán Hüttl; Béla Merkely
Journal:  Interv Med Appl Sci       Date:  2014-09-18

6.  Association of chronic renal insufficiency with in-hospital outcomes after percutaneous coronary intervention.

Authors:  Tanush Gupta; Neha Paul; Dhaval Kolte; Prakash Harikrishnan; Sahil Khera; Wilbert S Aronow; Marjan Mujib; Chandrasekar Palaniswamy; Sachin Sule; Diwakar Jain; Ali Ahmed; Howard A Cooper; William H Frishman; Deepak L Bhatt; Gregg C Fonarow; Julio A Panza
Journal:  J Am Heart Assoc       Date:  2015-06-16       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.